Sexually Transmitted Disease Surveillance 2023: Enhanced Gonococcal Isolate Surveillance Project Profiles

Division of STD Prevention
August 2025

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION
DIVISION OF STD PREVENTION
ATLANTA, GEORGIA 30329-4027

Acknowledgments

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Rebekah Frankson, Kristen Kreisel, Emily Rowlinson, and Luke Shouse, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Matthew Schmerer, Myriam Bèlanger, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, and LaShondra Berman and Eboni Galloway, Behavioral Science and Epidemiology Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2023: Enhanced Gonococcal Isolate Surveillance Project National Profile.* Atlanta: U.S. Department of Health and Human Services; 2025.

Web Site

The online version of this report is available at https://www.cdc.gov/sti-statistics/gisp-profiles/.

Technical Note

Antimicrobial susceptibility data presented in this report are based on criteria established by the Clinical & Laboratory Standards Institute (CLSI) and the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria (FDA-STIC).

2023 Enhanced Gonococcal Isolate Surveillance Project Clinical Sites and Years Participated

Columbus, Ohio *(2018-2019, 2023)*	Orange County, California *(2018–2023)*
Honolulu, Hawaii *(2023)*	Philadelphia, Pennsylvania *(2018–2023)*
Las Vegas, Nevada *(2018–2023)*	Phoenix, Arizona *(2020–2023)*
Minneapolis, Minnesota (2018–2019, 2023)	Pontiac, Michigan *(2018–2023)*
New Orleans, Louisiana *(2018–2023)*	San Diego, California *(2018–2023)*

2023 Enhanced Gonococcal Isolate Surveillance Project Regional Laboratories

Maryland Department of Health and Mental Hygeine *Baltimore, Maryland*
Tennessee Department of Health *Nashville, Tennessee*
Utah Department of Health *Salt Lake City, Utah*
Washington State Department of Health *Seattle, Washington*

2023 Enhanced Gonococcal Isolate Surveillance Project Profiles
Table of Contents

Figure 1. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	361	632	66	1059
Genital	2022	333	580	67	980
Genital	2023	380	534	60	974
Pharyngeal	2021	118	26	40	184
Pharyngeal	2022	136	34	43	213
Pharyngeal	2023	151	27	30	208
Rectal	2021	173	5	6	184
Rectal	2022	233	3	10	246
Rectal	2023	222	1	7	230

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Figure 2. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	855 (74.4)	221 (19.2)	39 (3.4)	32 (2.8)	2 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)	1149
Genital	2022	702 (70.8)	226 (22.8)	32 (3.2)	30 (3.0)	2 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)	992
Genital	2023	690 (68.5)	183 (18.2)	49 (4.9)	80 (7.9)	5 (0.5)	0 (0.0)	0 (0.0)	1 (0.1)	1008
Pharyngeal	2021	139 (61.8)	63 (28.0)	5 (2.2)	17 (7.6)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	225
Pharyngeal	2022	140 (63.1)	59 (26.6)	8 (3.6)	15 (6.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	222
Pharyngeal	2023	135 (59.2)	46 (20.2)	22 (9.6)	22 (9.6)	3 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	228
Rectal	2021	170 (63.2)	74 (27.5)	8 (3.0)	17 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	269
Rectal	2022	150 (57.9)	75 (29.0)	12 (4.6)	21 (8.1)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	259
Rectal	2023	164 (63.3)	49 (18.9)	20 (7.7)	23 (8.9)	3 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	259

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.
CLSI = Clinical & Laboratory Standards Institute.
Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.
As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 3. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	763 (66.4)	323 (28.1)	59 (5.1)	4 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1149
Genital	2022	671 (67.6)	282 (28.4)	35 (3.5)	4 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	992
Genital	2023	636 (63.1)	274 (27.2)	88 (8.7)	9 (0.9)	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	1008
Pharyngeal	2021	128 (56.9)	73 (32.4)	20 (8.9)	4 (1.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	225
Pharyngeal	2022	139 (62.6)	71 (32.0)	12 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	222
Pharyngeal	2023	111 (48.7)	81 (35.5)	33 (14.5)	3 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	228
Rectal	2021	153 (56.9)	92 (34.2)	23 (8.6)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	269
Rectal	2022	150 (57.9)	92 (35.5)	15 (5.8)	1 (0.4)	0 (0.0)	0 (0.0)	1 (0.4)	0 (0.0)	259
Rectal	2023	143 (55.2)	86 (33.2)	24 (9.3)	5 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.4)	259

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.
CLSI = Clinical & Laboratory Standards Institute.
Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.
As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 4. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	150 (13.1)	733 (63.8)	93 (8.1)	114 (9.9)	52 (4.5)	5 (0.4)	0 (0.0)	2 (0.2)	1149
Genital	2022	222 (22.4)	506 (51.0)	103 (10.4)	120 (12.1)	35 (3.5)	1 (0.1)	3 (0.3)	2 (0.2)	992
Genital	2023	157 (15.6)	541 (53.7)	102 (10.1)	139 (13.8)	54 (5.4)	1 (0.1)	9 (0.9)	5 (0.5)	1008
Pharyngeal	2021	21 (9.3)	128 (56.9)	27 (12.0)	40 (17.8)	9 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	225
Pharyngeal	2022	36 (16.2)	119 (53.6)	19 (8.6)	31 (14.0)	9 (4.1)	1 (0.5)	3 (1.4)	4 (1.8)	222
Pharyngeal	2023	19 (8.3)	117 (51.3)	26 (11.4)	40 (17.5)	22 (9.6)	0 (0.0)	0 (0.0)	4 (1.8)	228
Rectal	2021	13 (4.8)	168 (62.5)	27 (10.0)	41 (15.2)	20 (7.4)	0 (0.0)	0 (0.0)	0 (0.0)	269
Rectal	2022	33 (12.7)	142 (54.8)	21 (8.1)	41 (15.8)	19 (7.3)	1 (0.4)	0 (0.0)	2 (0.8)	259
Rectal	2023	20 (7.7)	155 (59.8)	36 (13.9)	29 (11.2)	17 (6.6)	0 (0.0)	0 (0.0)	2 (0.8)	259

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.
FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.
In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 5. Distribution of Ciprofloxacin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	≤0.015 n (%)	0.03-0.06 n (%)	0.125 n (%)	0.25-0.5 n (%)	1.0-2.0 n (%)	≥4.0 n (%)	Total
Genital	2021	664 (57.8)	13 (1.1)	8 (0.7)	48 (4.2)	88 (7.7)	328 (28.5)	1149
Genital	2022	576 (58.1)	14 (1.4)	16 (1.6)	66 (6.7)	78 (7.9)	242 (24.4)	992
Genital	2023	485 (48.1)	17 (1.7)	5 (0.5)	99 (9.8)	103 (10.2)	299 (29.7)	1008
Pharyngeal	2021	144 (64.0)	2 (0.9)	1 (0.4)	6 (2.7)	18 (8.0)	54 (24.0)	225
Pharyngeal	2022	122 (55.0)	1 (0.5)	3 (1.4)	8 (3.6)	20 (9.0)	68 (30.6)	222
Pharyngeal	2023	97 (42.5)	3 (1.3)	1 (0.4)	11 (4.8)	23 (10.1)	93 (40.8)	228
Rectal	2021	142 (52.8)	3 (1.1)	1 (0.4)	12 (4.5)	19 (7.1)	92 (34.2)	269
Rectal	2022	125 (48.3)	3 (1.2)	2 (0.8)	17 (6.6)	31 (12.0)	81 (31.3)	259
Rectal	2023	102 (39.4)	4 (1.5)	2 (0.8)	31 (12.0)	19 (7.3)	101 (39.0)	259

Ciprofloxacin resistance MIC ≥1.0 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 6. Distribution of Gentamicin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	16.0 n (%)	≥32.0 n (%)	Total
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	9 (0.8)	139 (12.1)	958 (83.4)	43 (3.7)	0 (0.0)	1149
Genital	2022	0 (0.0)	0 (0.0)	5 (0.5)	13 (1.3)	168 (16.9)	778 (78.4)	28 (2.8)	0 (0.0)	992
Genital	2023	0 (0.0)	0 (0.0)	3 (0.3)	12 (1.2)	160 (15.9)	716 (71.0)	107 (10.6)	10 (1.0)	1008
Pharyngeal	2021	0 (0.0)	0 (0.0)	1 (0.4)	3 (1.3)	30 (13.3)	177 (78.7)	14 (6.2)	0 (0.0)	225
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	3 (1.4)	48 (21.6)	164 (73.9)	7 (3.2)	0 (0.0)	222
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	28 (12.3)	178 (78.1)	22 (9.6)	0 (0.0)	228
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	28 (10.4)	229 (85.1)	12 (4.5)	0 (0.0)	269
Rectal	2022	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.8)	43 (16.6)	200 (77.2)	14 (5.4)	0 (0.0)	259
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24 (9.3)	219 (84.6)	15 (5.8)	1 (0.4)	259

As of publication, the Clinical & Laboratory Standards Institute (CLSI) criteria for susceptibility and resistance to gentamicin have not been established for *N. gonorrhoeae*. A GISP alert value for gentamicin has not been determined.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 7. Distribution of Penicillin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	58 (5.0)	420 (36.6)	387 (33.7)	161 (14.0)	56 (4.9)	18 (1.6)	20 (1.7)	29 (2.5)	1149
Genital	2022	66 (6.7)	364 (36.7)	356 (35.9)	111 (11.2)	30 (3.0)	23 (2.3)	18 (1.8)	24 (2.4)	992
Genital	2023	44 (4.4)	363 (36.0)	318 (31.5)	102 (10.1)	56 (5.6)	41 (4.1)	38 (3.8)	46 (4.6)	1008
Pharyngeal	2021	5 (2.2)	87 (38.7)	78 (34.7)	30 (13.3)	11 (4.9)	6 (2.7)	4 (1.8)	4 (1.8)	225
Pharyngeal	2022	6 (2.7)	69 (31.1)	81 (36.5)	34 (15.3)	13 (5.9)	7 (3.2)	4 (1.8)	8 (3.6)	222
Pharyngeal	2023	5 (2.2)	76 (33.3)	71 (31.1)	32 (14.0)	12 (5.3)	10 (4.4)	11 (4.8)	11 (4.8)	228
Rectal	2021	4 (1.5)	93 (34.6)	106 (39.4)	27 (10.0)	22 (8.2)	1 (0.4)	3 (1.1)	13 (4.8)	269
Rectal	2022	12 (4.6)	68 (26.3)	95 (36.7)	36 (13.9)	16 (6.2)	6 (2.3)	13 (5.0)	13 (5.0)	259
Rectal	2023	4 (1.5)	101 (39.0)	81 (31.3)	19 (7.3)	19 (7.3)	11 (4.2)	13 (5.0)	11 (4.2)	259

Penicillin resistance based on Clinical & Laboratory Standards Institute (CLSI) MIC criteria only (MIC ≥2.0 µg/mL).
Additional data on β-lactamase positivity are not depicted.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 8. Distribution of Tetracycline Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	1 (0.1)	99 (8.6)	284 (24.7)	536 (46.6)	65 (5.7)	10 (0.9)	1 (0.1)	153 (13.3)	1149
Genital	2022	4 (0.4)	107 (10.8)	233 (23.5)	470 (47.4)	45 (4.5)	8 (0.8)	4 (0.4)	121 (12.2)	992
Genital	2023	0 (0.0)	92 (9.1)	173 (17.2)	488 (48.4)	48 (4.8)	4 (0.4)	0 (0.0)	203 (20.1)	1008
Pharyngeal	2021	0 (0.0)	15 (6.7)	29 (12.9)	136 (60.4)	10 (4.4)	5 (2.2)	0 (0.0)	30 (13.3)	225
Pharyngeal	2022	0 (0.0)	21 (9.5)	43 (19.4)	109 (49.1)	8 (3.6)	1 (0.5)	1 (0.5)	39 (17.6)	222
Pharyngeal	2023	0 (0.0)	15 (6.6)	29 (12.7)	116 (50.9)	14 (6.1)	2 (0.9)	0 (0.0)	52 (22.8)	228
Rectal	2021	1 (0.4)	21 (7.8)	32 (11.9)	159 (59.1)	18 (6.7)	1 (0.4)	0 (0.0)	37 (13.8)	269
Rectal	2022	0 (0.0)	27 (10.4)	34 (13.1)	133 (51.4)	10 (3.9)	0 (0.0)	3 (1.2)	52 (20.1)	259
Rectal	2023	0 (0.0)	16 (6.2)	29 (11.2)	145 (56.0)	11 (4.2)	1 (0.4)	0 (0.0)	57 (22.0)	259

Tetracycline resistance MIC ≥2.0 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 9. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	1 (0.3)	1 (0.2)	0 (0.0)	2
Genital	2022	0 (0.0)	2 (0.3)	0 (0.0)	2
Genital	2023	1 (0.3)	5 (0.9)	0 (0.0)	6
Pharyngeal	2021	0 (0.0)	0 (0.0)	1 (2.5)	1
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2023	2 (1.3)	0 (0.0)	1 (3.3)	3
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	1 (0.4)	0 (0.0)	0 (0.0)	1
Rectal	2023	3 (1.4)	0 (0.0)	0 (0.0)	3

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Cefixime elevated MIC ≥0.25 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 10. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Genital	2023	0 (0.0)	1 (0.2)	0 (0.0)	1
Pharyngeal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2022	0 (0.0)	0 (0.0)	0 (0.0)	0
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2022	1 (0.4)	0 (0.0)	0 (0.0)	1
Rectal	2023	1 (0.5)	0 (0.0)	0 (0.0)	1

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Ceftriaxone elevated MIC ≥0.125 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 11. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	29 (8.0)	23 (3.6)	3 (4.5)	55
Genital	2022	21 (6.3)	18 (3.1)	2 (3.0)	41
Genital	2023	27 (7.1)	33 (6.2)	5 (8.3)	65
Pharyngeal	2021	3 (2.5)	1 (3.8)	4 (10.0)	8
Pharyngeal	2022	11 (8.1)	2 (5.9)	4 (9.3)	17
Pharyngeal	2023	18 (11.9)	4 (14.8)	3 (10.0)	25
Rectal	2021	18 (10.4)	0 (0.0)	0 (0.0)	18
Rectal	2022	19 (8.2)	1 (33.3)	1 (10.0)	21
Rectal	2023	14 (6.3)	0 (0.0)	2 (28.6)	16

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Azithromycin resistance ≥2.0 µg/mL. (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as ≥2.0 µg/mL).
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 12. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	135 (37.4)	230 (36.4)	21 (31.8)	386
Genital	2022	131 (39.3)	164 (28.3)	21 (31.3)	316
Genital	2023	182 (47.9)	181 (33.9)	23 (38.3)	386
Pharyngeal	2021	48 (40.7)	5 (19.2)	6 (15.0)	59
Pharyngeal	2022	60 (44.1)	13 (38.2)	11 (25.6)	84
Pharyngeal	2023	82 (54.3)	10 (37.0)	14 (46.7)	106
Rectal	2021	76 (43.9)	4 (80.0)	2 (33.3)	82
Rectal	2022	99 (42.5)	0 (0.0)	3 (30.0)	102
Rectal	2023	101 (45.5)	0 (0.0)	4 (57.1)	105

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Ciprofloxacin resistance = MIC ≥1.0 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 13. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Penicillin by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	48 (13.3)	68 (10.8)	10 (15.2)	126
Genital	2022	57 (17.1)	46 (7.9)	6 (9.0)	109
Genital	2023	111 (29.2)	74 (13.9)	5 (8.3)	190
Pharyngeal	2021	19 (16.1)	2 (7.7)	3 (7.5)	24
Pharyngeal	2022	23 (16.9)	8 (23.5)	3 (7.0)	34
Pharyngeal	2023	35 (23.2)	2 (7.4)	3 (10.0)	40
Rectal	2021	25 (14.5)	1 (20.0)	1 (16.7)	27
Rectal	2022	50 (21.5)	0 (0.0)	2 (20.0)	52
Rectal	2023	48 (21.6)	0 (0.0)	0 (0.0)	48

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Penicillin resistance ≥2.0 µg/mL or β-lactamase positive.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Figure 14. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Tetracycline by Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021-2023



Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total
Genital	2021	90 (24.9)	107 (16.9)	12 (18.2)	209
Genital	2022	85 (25.5)	80 (13.8)	8 (11.9)	173
Genital	2023	139 (36.6)	98 (18.4)	9 (15.0)	246
Pharyngeal	2021	33 (28.0)	1 (3.8)	4 (10.0)	38
Pharyngeal	2022	30 (22.1)	10 (29.4)	7 (16.3)	47
Pharyngeal	2023	47 (31.1)	4 (14.8)	7 (23.3)	58
Rectal	2021	42 (24.3)	2 (40.0)	1 (16.7)	45
Rectal	2022	57 (24.5)	0 (0.0)	2 (20.0)	59
Rectal	2023	60 (27.0)	0 (0.0)	1 (14.3)	61

MSM = Men who have sex with men; MSW = Men who have sex with women only.
Tetracycline resistance ≥2.0 µg/mL.
Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.